Clinical Trial

Effectiveness and Safety of Palbociclib: Brand vs. Generic in Iraqi Stage IV Breast Cancer Patients

Study acronym: PALLAS-IRAQ
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
This study aims to evaluate the efficacy and safety of branded palbociclib (Ibrance®) compared to available local generic formulations (Palbociclib-IPI) in Iraqi patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (HR+ HER2- BC). This research aims to provide evidence
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-03-19.
Trial Details
NCT Number NCT07493291
Lead Sponsor Al-Mustansiriyah University
Collaborators: Al-Anbar Health Organization
Conditions Brest Cancer, CDK4/6 Inhibitor
Enrollment 100 participants
Start Date 2025-09-07
Primary Completion 2026-03-01 (estimated)
Study Completion 2026-04-20 (estimated)
Updated on ClinicalTrials.gov 2026-03-30